BSG and susceptibility to pneumonia measurement: Currently, a Phase II clinical trial titled “Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia” (ClinicalTrials.gov Identifier: NCT04275245) is underway in China to evaluate the efficacy of monoclonal-antibody-mediated CD147 blockade in preventing viral SP interaction and infection [39].